62 research outputs found
Ustekinumab as Induction and Maintenance Therapy for Crohn’s Disease
BACKGROUND
Ustekinumab, a monoclonal antibody to the p40 subunit of interleukin-12 and inter-leukin-23, was evaluated as an intravenous induction therapy in two populations with moderately to severely active Crohn’s disease. Ustekinumab was also evaluated as subcutaneous maintenance therapy.
METHODS
We randomly assigned patients to receive a single intravenous dose of ustekinumab (either 130 mg or approximately 6 mg per kilogram of body weight) or placebo in two induction trials. The UNITI-1 trial included 741 patients who met the criteria for primary or secondary nonresponse to tumor necrosis factor (TNF) antagonists or had unacceptable side effects. The UNITI-2 trial included 628 patients in whom conventional therapy failed or unacceptable side effects occurred. Patients who completed
these induction trials then participated in IM-UNITI, in which the 397 patients who had a response to ustekinumab were randomly assigned to receive subcutaneous maintenance injections of 90 mg of ustekinumab (either every 8 weeks or every 12 weeks) or placebo. The primary end point for the induction trials was a clinical response at week 6 (defined as a decrease from baseline in the Crohn’s Disease Activity Index [CDAI] score of ≥100 points or a CDAI score <150). The primary end point for the maintenance trial was remission at week 44 (CDAI score <150).
RESULTS
The rates of response at week 6 among patients receiving intravenous ustekinumab at a dose of either 130 mg or approximately 6 mg per kilogram were significantly higher
than the rates among patients receiving placebo (in UNITI-1, 34.3%, 33.7%, and 21.5%, respectively, with P≤0.003 for both comparisons with placebo; in UNITI-2, 51.7%, 55.5%, and 28.7%, respectively, with P<0.001 for both doses). In the groups receiving maintenance doses of ustekinumab every 8 weeks or every 12 weeks, 53.1% and 48.8%, respectively, were in remission at week 44, as compared with 35.9% of those receiving placebo (P = 0.005 and P = 0.04, respectively). Within each trial, adverse-event rates were similar among treatment groups.
CONCLUSIONS
Among patients with moderately to severely active Crohn’s disease, those receiving intravenous ustekinumab had a significantly higher rate of response than did those receiving placebo. Subcutaneous ustekinumab maintained remission in patients who had a clinical response to induction therapy. (Funded by Janssen Research and Development; ClinicalTrials.gov numbers, NCT01369329, NCT01369342, and NCT01369355.
Midsouth Entomologist A Novel Delivery Method for Ant (Hymenoptera: Formicidae) Toxicants
Abstract: Described here is a new delivery method for ant toxicants consisting of an inert carrier, an attractant, and a toxicant. Unlike baits, this system does not contain a food source, but uses ant to ant contact rather than trophallaxis as the mechanism for horizontal dispersal of the toxicant through the colony. We evaluated six potential attractants and found that only triolein increased treated filter paper removal by the red imported fire ant, Solenopsis invicta Buren (Hymenoptera: Formicidae). On corn cob grits, removal was optimized at a rate of 60 ÎĽl triolein/g grits. In laboratory assays, mortality of fire ants offered corn cob grits treated with a combination of fipronil and triolein was 90.5%, versus 46.5% when grits were treated with the same rate of fipronil without triolein. In both lab and field trials, the removal of grits treated with a combination of fipronil and triolein was greater than removal of controls but less than removal of grits treated with triolein alone
Navier-Stokes analyses of the redistribution of inlet temperature distortions in a turbine
- …